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Gretchen N. de Graav, MD, PhD,1 Marieke van der Zwan, MD,1 Carla C. Baan, MD, PhD,1
Joop A.M.J.L. Janssen, MD, PhD,2 and Dennis A. Hesselink, MD, PhD1Abstract: The introduction of immunosuppressant belatacept, an inhibitor of the CD28-80/86 pathway, has improved 1-year
outcomes in kidney transplant recipients with preexistent diabetes mellitus and has also reduced the risk of posttransplant diabe-
tes mellitus. So far, no studies have compared a tacrolimus-based with a belatacept-based immunosuppressive regimen with re-
gard to improving glucose tolerance after kidney transplantation. Here, we present the case of a 54-year-old man with type 2
diabetes mellitus who was converted from belatacept to tacrolimus 1 year after a successful kidney transplantation. Thereafter,
he quickly developed severe hyperglycemia, and administration of insulin was needed to improve metabolic control. Six months
after this episode, he was converted back to belatacept because of nausea, diarrhea, and hyperglycemia. After switching back
to belatacept and within 4 days after stopping tacrolimus glucose tolerance improved and insulin therapy could be discontinued.
Although belatacept is considered less diabetogenic than tacrolimus, the rapid improvement of glucose tolerance after switching
to belatacept is remarkable. In this article, the potential mechanisms of this observation are discussed.
(Transplantation Direct 2018;4: e350; doi: 10.1097/TXD.0000000000000767. Published online 20 February, 2018.)K idney transplant recipients who have preexistent diabe-tes mellitus (DM) or who develop DM after transplan-
tation (posttransplant DM [PTDM]) have a worse survival
and suffer from more cardiovascular morbidity than those
without.1-3 The calcineurin inhibitors (CNI), cyclosporine A
(CsA) and tacrolimus, may decrease insulin secretion and in-
crease insulin resistance.4 The latter is characterized by a de-
creased insulin sensitivity, that is, more insulin is needed to
maintain serum glucose within the reference range.5Received 28 November 2017. Revision requested 29 December 2017.
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Transplantation DIRECT ■ 2018Belatacept, an inhibitor of the CD28-CD80/86 pathway,6
does not induce hyperglycemia nor PTDM. Despite the
higher acute rejection risk observed in belatacept-treated pa-
tients,7-9 it improves 1-year allograft survival and renal func-
tion in kidney transplant recipients with preexistent DM
compared with CsA-treated patients.3
In addition, belatacept-based therapy decreases the risk of
developing PTDM. A meta-analysis which included 729
belatacept-treated and 320 CsA-treated patients showed a rela-
tive risk of 0.61 (95%-confidence interval, 0.40-0.93) to develop
PTDMwith belatacept compared to CsA.10 Tacrolimus is, now-
adays, the most widely used CNI, and treatment with tacrolimus
carries a higher risk of developing PTDM than CsA.11,12Center Rotterdam, Rm Na-523, P.O. Box 2040, 3000 CA, Rotterdam, The
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2 Transplantation DIRECT ■ 2018 www.transplantationdirect.comBelatacept may be a therapeutic option for kidney trans-
plant recipients that develop PTDM or for those with preex-
istent DMwho develop worsening of metabolic control after
starting a CNI-based regimen. Glucose metabolism has not
been compared between belatacept- and tacrolimus-treated
patients. In addition, no data on the safety and efficacy re-
garding insulin sensitivity of conversion from CNIs to
belatacept after kidney transplantation have been reported.
Here, a kidney transplant recipient with DM is described,
who after conversion from belatacept to tacrolimus devel-
oped severe hyperglycemia. Glucose control was difficult and
did not improve despite high doses of insulin. Within 4 days
after stopping tacrolimus and reintroducing belatacept, a
marked improvement of glucose tolerance was observed.
The purpose of this case report is to discuss the possible path-
ophysiologic mechanisms explaining this observation and
the role of immunosuppressive therapy therein.CASE DESCRIPTION
A 54-year-old white man received a preemptive, living-
unrelated donor kidney transplant in October 2013 because
of hypertensive and diabetic nephropathy. His medical his-
tory included hypertension since 1992; type 2 DM since
2002; and since 2008, histologically confirmed diabetic and
hypertensive nephropathies. The transplant was 2-2-1 mis-
matched (for HLA-A, HLA-B, and HLA-DR, respectively).
Peak and actual panel reactive antibodies were 0%.FIGURE 1. Overview of the dose of tacrolimus and prednisolone. The d
time period. Tacrolimus was adjusted to whole blood predose concentra
on days 0 to 3. From day 4 until day 18 the prednisolone dose was 20mg
5 to 6 the prednisolone dose was 10mg/d; in weeks 7 to 10 the prednis
The dashed vertical lines indicate the time points when belatacept wasThe patient was treated with belatacept according to the
less-intensive regimen of the Belatacept Evaluation of
Nephroprotection and Efficacy as First-line Immunosuppres-
sion trials during the first posttransplantation year as part of
a randomized-controlled trial.13,14 This trial compared
belatacept with tacrolimus, and its main findings were described
previously.14,15 In addition to belatacept, he also received induc-
tion therapywith 20mg/kg basiliximab (days 0 and4) andmain-
tenance therapywithmycophenolatemofetil (targeted to predose
concentrations of 1.5-3.0 mg/mL), and prednisolone, tapered to
5 mg/d by month 3 and maintained at 5 mg/d thereafter
(Figure 1). The clinical course of the first posttransplant year
was uneventful. Belatacept was not reimbursed by the
health insurance companies in the Netherlands at the time
the patient was 1 year after transplantation (October
2014). Belatacept was discontinued, and he was switched
to tacrolimus (Advagraf; Astellas Pharma, Tokyo, Japan) tar-
geted to predose concentrations of 5 to 7 ng/mL (Figure 1).
At the time of transplantation, his DM was well con-
trolled: glycated hemoglobin (HbA1c) was 44 mmol/mol
with 24 International Units (IU) of long-acting insulin-
glargine (Lantus; Sanofi, Paris, France) daily. Before trans-
plantation, he was taken care of by a nephrologist in a local
hospital. Initially, his diabetes was managed with metformin
only. When his renal function deteriorated, metformin was
stopped, and he was started on long-acting insulin. After
transplantation and in an attempt to take patient off insulin,
he was started on metformin and glimepiride. Insulin-epicted doses of tacrolimus and prednisolone are oral daily doses per
tions (C0). Prednisolone was given as an intravenous dose of 100 mg
/d; in weeks 3 to 4 the prednisolone dose was 15 mg/d; in weeks
olone dose was 7.5 mg/d; thereafter, prednisolone dose was 5 mg/d.
discontinued and restarted.
© 2018 Wolters Kluwer de Graav et al 3glargine was initially continued (mean dose, 28 IU/d). In ad-
dition, during the first month after transplantation, he re-
ceived short-acting insulin-aspart (NovoRapid; Novo
Nordisk, Bagsværd, Denmark, mean dose 18 IU/d). Four
months after his transplantation and when prednisolone
had been tapered to 5mg daily, insulin could be discontinued
completely. Figure 2 gives an overview of diabetes-related
events, glucose and HbA1c concentrations, and glucose low-
ering medication. We believe that the combination of im-
proved kidney function, possibly increased physical activity,
the introduction of metformin and glimepiride and the taper-
ing of prednisolone to 5 mg daily (Figure 2) allowed for the
complete withdrawal of insulin therapy.
Within 14 days after conversion to tacrolimus, the patient de-
veloped severe hyperglycemic episodes (Figure 2). Glimepiride
and metformin were increased to 6 mg and 3000 mg daily,
respectively, without improvement of glucose control (Figure 2).FIGURE 2. Overview of diabetes-related events, measurements, and g
tant events related to changes in glucose concentrations. The presente
the outpatient clinic. The maximum target concentration of HbA1c was 5
cluded. The daily doses per period are given for metformin, glimepiride, in
tation, doses of insulin-aspart were adjusted to target a premeal gluco
dashed vertical lines indicate the time points when belatacept was discoInsulin therapy was restarted (Figure 2). The patient needed
up to 50 IU of short- and long-acting insulin on a daily basis
to improve metabolic control. Despite the high insulin dose,
hyperglycemia persisted. During these hyperglycemic epi-
sodes, no infections or changes in bodyweight were observed.
In addition, the patient developed tremors of the hands,
nausea, and diarrhea that were all considered as side effects
of tacrolimus. Clinically, no signs of tacrolimus-associated
nephrotoxicity were observed. No (protocol) kidney biopsy
was performed after conversion to tacrolimus. Because of
these side effects, 6 months after conversion, belatacept
(5 mg/kg bodyweight monthly) was restarted. Tacrolimus
was discontinued overnight. Four days after discontinuing
tacrolimus, the patient’s blood glucose concentrations im-
proved tremendously, and insulin therapy could be stopped.
During the 2-year follow-up period, the patient has re-
mained in good clinical condition. No acute rejectionlucose-lowering medication. A timeline is depicted, indicating impor-
d glucose and HbA1c concentrations were measured in hospital at
3 mmol/mol. Glucose concentrations measured at home are not in-
sulin-glargine, and insulin-aspart. From days 12 to 48 after transplan-
ses concentration of <10 mmol/L (average dose was 18 IU/d). The
ntinued and restarted.
4 Transplantation DIRECT ■ 2018 www.transplantationdirect.comoccurred, and his eGFR has remained stable (55mL/min per
1.73 m2; Figure S1, http://links.lww.com/TXD/A63). His
current glucose-lowering treatment consists of metformin
and glimepiride.DISCUSSION
In this patient, a marked improvement in glucose tolerance
was observed after switching from belatacept to tacrolimus.
Improvement of glucose control occurred immediately after
withdrawal of tacrolimus and exogenous insulin could be
stopped within 4 days. The improvement in glucose was
not related to changes in BMI (Figure S1, http://links.lww.
com/TXD/A63). Although it is well known that belatacept
is less diabetogenic than CNIs,10 the rapid improvement of
glucose tolerance was remarkable and unexpected.
Tacrolimus may induce DM by several mechanisms. First,
tacrolimus reduces insulin secretion by the pancreatic β cells
via decreasing insulin mRNA expression through inhibition
of 2 pathways (nuclear factor of activated T cells and cAMP
response element-binding protein).16-19 Second, the insulin
content of the β cell is diminished by tacrolimus.17 Third,
the glucose-induced insulin release is inhibited by tacrolimus
through reduced glucokinase activity.17,20 Fourth, tacrolimus
directly induces β cell apoptosis and reduces islet cell prolif-
eration.19,21 Altogether, these effects lead to a reduction of in-
sulin secretion. Furthermore, CNIs may induce insulin
resistance by stimulating endocytic removal of glucose trans-
porter type 4 (Glut-4) from the cell membrane of adipocytes
and muscle cells.22
The induction of hypomagnesemia is another mechanism
by which tacrolimus may directly influence glucose toler-
ance.23 Tacrolimus can downregulate the magnesium ab-
sorbing channel transient receptor of potential melastatin
(TRPM6) in the distal collecting tubule and thereby induce
hypomagnesemia via renalmagnesiumwasting.24Hypomag-
nesemia may contribute to insulin resistance by decreasing
autophosphorylation of the β subunits of the insulin recep-
tor.25 Besides, hypomagnesemia may reduce insulin secre-
tion.25 Unfortunately, it is unknown if hypomagnesemia
played a role in our case, because magnesium concentrations
were not measured.
We think that the fast improvement of glucose control af-
ter switching to belatacept in our patient was mainly re-
lated to (1) the discontinuation of tacrolimus and/or (2) a
direct effect on insulin resistance by CD80-86 blockade
by belatacept. Several animal studies have described the ef-
fects of discontinuation of tacrolimus on glucosemetabolism.
Redmon et al17 observed reversibility of insulin secretion
72 hours after discontinuation of tacrolimus in hamster
β-cells (HIT-T15). Another in vitro study using rat β cells
found similar results.26 In an in vivo study, reversibility of
rat β cells insulin gene expression, insulin content, and in-
sulin secretion was observed 7 days after discontinuing ta-
crolimus.27 Another study in rats showed that the insulin
resistance improved 5 days after the last dose of tacrolimus.28
All these studies show reversibility of impaired glucose tol-
erance after discontinuation of tacrolimus. However, these
studies are limited by the short duration of tacrolimus treat-
ment. Prolonged administration could possibly lead to a
more severe reduction of functional β-cell mass and irrevers-
ibility of impaired glucose control. Furthermore, to the bestof our knowledge, no studies in humans have analyzed di-
rectly the effects of insulin secretion and resistance after dis-
continuation of tacrolimus. Boots et al29 described the effect
of tacrolimus dose reduction on insulin secretion. In 15 kid-
ney transplant recipients without DM, a 33% reduction in
the tacrolimus predose concentrations resulted in a 36% in-
crease in β cell secretion capacity.29
The fast improvement of glucose tolerance in this casemay
also have been caused by the introduction of belatacept
(rather than the withdrawal of tacrolimus). One study has
suggested that CD86 may play a role in insulin resistance
via interaction with the adiponectin axis.30
Interestingly, a case report of a patient with rheumatoid ar-
thritis reported an improvement of insulin resistance 4 weeks
after treatment with abatacept, which is considered a lower-
affinity version of belatacept.31 In another study, improved
insulin sensitivity was observed in 15 patients 6 months after
the start of abatacept treatment.32
In contrast to the findings of the studies described above,
Zhong et al33 found in mice and humans that a higher
CD80/86 expression was negatively correlated with insulin
resistance. No effect of adiponectin on CD80/86 expression
was noted on human macrophages in another study.34
The main limitation of this case report is that the mecha-
nistic evidence of the effect of belatacept and tacrolimus on
glucose tolerance is lacking.We did not examine endogenous
insulin secretion and insulin resistance.
In conclusion, a kidney transplant recipient with preexist-
ing type 2 DM is described who showed a rapid improve-
ment of glucose tolerance after switching from tacrolimus
to belatacept. Such a strategy may be beneficial in compara-
ble cases although high-quality evidence of the safety of this
intervention in terms of rejection is currently lacking.REFERENCES
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